Media enquiries
Thank you for your message!
We will examine it with utmost attention and get back to you shortly.
Do you have
any question?
Saint-Cloud, France – April 6th, 2021 – Ethypharm announces today that it has acquired exclusive rights for two CE-marked digital therapies, deprexis® and vorvida®, developed by GAIA AG (GAIA), a global leader in digital therapeutics. With these innovative clinically-proven digital therapies, Ethypharm strengthens its product offering to support patients and healthcare providers in its core area of the Central Nervous System (CNS) where there are significant unmet needs.
Thank you for your message!
We will examine it with utmost attention and get back to you shortly.